Shares of Meridian Bioscience Inc. (NASDAQ:VIVO) have earned a consensus rating of “Hold” from the eight research firms that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation and six have given a hold recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $12.00.

A number of brokerages have commented on VIVO. Zacks Investment Research raised shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a research note on Saturday, April 29th. Canaccord Genuity raised their target price on shares of Meridian Bioscience from $13.00 to $15.00 and gave the stock a “hold” rating in a report on Wednesday, May 3rd. CL King assumed coverage on shares of Meridian Bioscience in a report on Tuesday, March 28th. They issued a “neutral” rating for the company. Finally, BidaskClub lowered shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Thursday, July 6th.

COPYRIGHT VIOLATION NOTICE: “Meridian Bioscience Inc. (VIVO) Given Consensus Rating of “Hold” by Analysts” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/07/17/meridian-bioscience-inc-vivo-given-consensus-rating-of-hold-by-analysts.html.

Several large investors have recently added to or reduced their stakes in the company. Louisiana State Employees Retirement System raised its stake in Meridian Bioscience by 1.8% in the first quarter. Louisiana State Employees Retirement System now owns 17,200 shares of the company’s stock valued at $237,000 after buying an additional 300 shares during the period. Arizona State Retirement System raised its stake in Meridian Bioscience by 1.4% in the first quarter. Arizona State Retirement System now owns 21,941 shares of the company’s stock valued at $303,000 after buying an additional 300 shares during the period. RiverPoint Capital Management LLC raised its stake in Meridian Bioscience by 2.9% in the first quarter. RiverPoint Capital Management LLC now owns 20,965 shares of the company’s stock valued at $289,000 after buying an additional 599 shares during the period. Mason Street Advisors LLC raised its stake in Meridian Bioscience by 7.2% in the first quarter. Mason Street Advisors LLC now owns 9,868 shares of the company’s stock valued at $136,000 after buying an additional 667 shares during the period. Finally, Thrivent Financial For Lutherans raised its stake in Meridian Bioscience by 3.9% in the first quarter. Thrivent Financial For Lutherans now owns 23,640 shares of the company’s stock valued at $326,000 after buying an additional 890 shares during the period. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Meridian Bioscience (NASDAQ:VIVO) opened at 15.15 on Monday. The stock’s 50 day moving average is $14.67 and its 200 day moving average is $14.55. The company has a market capitalization of $639.36 million, a P/E ratio of 21.37 and a beta of 0.90. Meridian Bioscience has a 52 week low of $10.75 and a 52 week high of $20.54.

Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings data on Friday, April 28th. The company reported $0.22 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.03. Meridian Bioscience had a net margin of 15.02% and a return on equity of 18.02%. The business had revenue of $54.13 million during the quarter, compared to analysts’ expectations of $51.16 million. During the same period last year, the company posted $0.24 EPS. The business’s revenue was up 5.6% on a year-over-year basis. On average, equities research analysts expect that Meridian Bioscience will post $0.68 earnings per share for the current year.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.

Analyst Recommendations for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.